Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Grace Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 14 | 13 | −1 |
| Shares | 179.0K | 197.4K | +18.4K (+10.3%) |
| Value | $356.5K | $248.8K | −$107.6K (−30.2%) |
New holders (3)
Institutions that held Grace Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| National Bank of Canada | 17,456 | $22.0K | 0.00% |
| Koshinski Asset Management, Inc. | 2,000 | $2.52K | 0.00% |
| Toronto Dominion Bank | 82 | $0 | 0.00% |
Sold out (4)
Institutions that held Grace Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Citadel Advisors LLC | 36,571 | $73.0K |
| Virtu Financial LLC | 27,100 | $54.0K |
| UBS Group AG | 4,500 | $9.00K |
| Brewin Dolphin Ltd | 3 | $6 |